SUMMARY Karyotypes of bone marrow cells from 24 patients with multiple myeloma (MM) and two patients with de novo plasma cell leukaemia (PCL) were analysed by Giemsa banding (G banding). Chromosome aberrations were found in 13 patients with MM and both patients with PCL. Hyperdiploid and hypodiploid lines were present in eight and five of the patients with MM, respectively. Marker chromosomes derived from structural rearrangements were present in all eight cases of MM with hyperdiploid lines, although markers of uncertain origin were rare in those patients with hypodiploid lines. Chromosome 1 participated most often, and chromosomes 5 and 9 often played a part in the structural rearrangements. Chromosomes 3, 5, 7, 9, 11, 15, 19, and 21 were subject to numerical aberrations. In the two patients with PCL one had a hypodiploid line with a 14q + marker derived from a t(I 1; 14) and the other a hyperdiploid line. The breakpoints on the chromosomes participating in the structural rearrangements in myeloma showed a good correlation with known fragile sites and oncogene locations on the corresponding chromosomes.
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Multiple myeloma is a neoplasm of the B cell line characterised by a monoclonal proliferation of plasma cells which, with rare exceptions, secrete whole immunoglobulins or immunoglobulin light chains. The bone marrow is commonly affected. Cytogenic studies on the myeloma cells show that chromosomal abnormalities have a role in the development of the disease. In prebanding studies 25% of patients with myeloma were found to have abnormal cell lines in their bone marrows.' Hyperdiploidy was observed more commonly than hypodiploidy and pseudodiploidy. Large metacentric, submetacentric, and acrocentric markers were often described, usually with no convincing consistency in their morphology from patient to patient.1 7 The application of chromosome banding techniques has facilitated the analysis of the various marker chromosomes in myeloma cells. Chromosomal aberrations are found to entail the activity of most of the autosomes in the genome. There is extensive participation of chromosome 1 and considerable participation of chromosome 3 in the structural rearrangements.8 -' 1 Several vulnerable break points are located on these chromosomes as well as on chromosomes 5, 6, 7, 9, 11, and 22. The rearrangements between these chromosomes give rise to the morphologically various markers in myeloma. Chromosome 14 is also subject to marker formation. The 14q + marker, often described in myeloma and PCL, The immunoglobulin light chain proteins are not typed in all the patients. Bone marrow cells were cultured for one to four Results days in tissue culture media without the addition of mitogens. Three kinds of media were used-McCoy's Table 1 shows the chromosome counts in the 24 pa-(Gibco), Iscove's (Gibco), and modified Iscove's (Im-tients with MM and the two with PCL. A sufficient perial Laboratories, Salisbury). Mitotic cells were number of metaphase cells analysed by Gbanding harvested, and chromosome preparations were was obtained in the 20 cases of MM and both cases of G banded by standard 2xSSC/trypsin-Giemsa PCL. Cells with karyotypic abnormalities were scored method.
in 13 cases of MM (1 to 13). Case 14 had aneuploid Table 2 gives the designation of abnormal karyotypes and marker chromosomes as determined by G banding in the 13 patients with MM and the two with PCL. Fig. 1 , 5, 6, 9, 12, 14, and 20. Eight of the patients with MM had hyperdiploid lines in the bone marrow. Cases 4 and 8 had high chromosome counts of 74-84 and 63. The karyotypes (Table 2) indicated that these cells were derived from tetraploid cells following the loss of some chromosomes from their tetraploid genomes. In case 4 further structural changes occurred between the additional chromosomes, which gave rise to variable numbers of markers of uncertain origin in the abnormal cells. In this patient's marrow about half of the mitotic cells were hyperdiploid with consistent reciprocal translocation between chromosomes 11 and 14 and an extra 14q + marker. Four patients (3, 7, 9, and 10) had hyperdiploid lines with chromosome counts around 52 to 55. Extra chromosomes 3, 5, 7, 9, 11, 15, 19. and 264 Chen, Bevan, Matthews 21 were present in these hyperdiploid cells. Derived diploid cells of case 10 had an abnormal karyotype in structural changes were common in the side line ab-which there was an extra band on the long arm of one normal cells, with chromosomes 1, 5, and 9 par-chromosome 9 ( Fig. 1) . One of the cells examined had ticipating often. Marker chromosomes of uncertain an additional translocation between chromosome origin were common in these hyperdiploid cases. The 2 and 7, which gave rise to an acrocentric and a Table 2 . Known fragile sites (*), oncogenes (0), and break points of neoplastic disease (arrows) of corresponding chromosomal regions are also plotted and indicated below chromosomes. AML = Acute myeloid leukaemia; CML = chronic myeloid leukaemia; B CLL = Bcell chronic lymphocytic leukaemia; pre-B-ALL = pre-B cell-type acute lymphocytic leukaemia; NHL = Non-Hodgkin's lymphoma; T-Lym = Tcell lymphoma; BL = Burkitt's lymphoma; FL = follicular lymphoma; ES = Ewing sarcoma; Ova Ca = ovarian cancer; Neu = neuroepithelioma.
dicentric chromosome marker (Fig. 1) 3, 5, 6, 7, 8, 11, 16, 20, and A 14q + marker chromosome, which is commonly associated with B lymphocyte neoplasia, was found in only one of the 13 patients with MM with abnormal lines. It has been suggested that the appearance of the 14q+ marker may be associated with the development of a leukaemic phase in myeloma. [9] [10] [11] [12] On the other hand, the banding studies in patients with PCL indicate that 14q + seems to be a consistent marker for PCL.9 10 One of the patients with PCL in this study had a 14q + consistent marker derived from a t(l 1;14) in the hypodiploid line.
Despite the heterogeneity in the chromosome composition of myeloma cells there were non-random vulnerable regions of breakage on a few chromosomes. When these break points were plotted and compared with the known chromosomal fragile sites and oncogene regions, as defined by Yunis and Soreng,16 the coincidence was striking. Eleven break points were located at or near the fragile sites. Six break points coincided with the oncogene sites. Nine break points occurred at the vulnerable spots that play a part in specific translocations found in acute leukaemias and lymphomas (Fig. 2) . Studies in different haematological diseases have shown that chromosome break points of several specific translocations coincide with the fragile sites and oncogene locations.17 These may be important in oncogenesis-for example, in Burkitt's lymphoma, in which a translocation acts by joining the c-myc oncogene on chromosome 8 close to one of the immunoglobulin loci normally active in B lymphocytes, resulting in a constitutive activation of the oncogene.1" A neoplastic phenotype develops by a multistep process. The heterogeneity of the chromosome aberrations found in myeloma cells reflects the complexity Chen, Bevan, Matthews of the regulation of plasma cell development. As in other haematological disorders, the genetic mechanisms of chromosomal rearrangements, in association with the fragile sites and oncogenes, may apply to myeloma as well as to other malignant conditions.
